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Abstract 
The research was conducted to know the effect of amikacin administrations to the concentration of drug in reptile. The 16 
sanca batik snakes (Broghammerus reticulatus) were adapted then  divided into  four  groups of  which each was administered  
5 mg · kg–1 body weight of amikacin by posterior and anterior intravenous and intramuscular injection, respectively. The blood 
collection was done by cardio-puncture to each group at minute 1, 60 and 24, 48 h after drug injection and the drug concentration 
was analysed by High Performance Liquid Chromatography. The result showed that the drug by i.v. or i.m. administration routes 
(t1,t48) from posterior region had higher concentrations (81.90 ± 23.1) mg · mL–1, (17.23 ± 5.29) mg · mL–1) compared to the 
anterior injection (P < 0.01). The other concentration comparisons between regions resulted in no significant difference. 
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Nomenclature 
 
d day, time of sampling interval                       i.v.          intravenously 
h  hour, time of sampling interval                     i.m.         intramuscularly 
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1. Introduction 
Many studies of aminoglycosides including amikacin were conducted in reptiles and revealed the effectiveness 
of the drug in snakes, alligators or turtles. The drug seems to be frequently used to treat Gram negative bacterial 
infections in reptiles although it has nephrotoxic potential1,2. The recent experiments mainly studied in 
pharmacology field are related to physiology and environment as factors which influenced the effectiveness of 
drug3,4. There were still minimum data of amikacin as therapeutic agent used in snake or reptile. A trial of doses 
ranging from (2.5 to 5) mg · kg–1 body weight had been used to gopher snake4  to find the optimum dosage. The 
ambient temperature effects on dosages in balls python3 or disposition kinetics of drug in juvenile American 
alligators1 were also studied. The other pharmacokinetic and administrations of drug studied resulted in some 
pharmacokinetic parameters and effectiveness of some antimicrobials commonly infectious in reptile1,2,5. However, 
the significant issue of administration of the drug in reptile was the consideration of renal-portal system which might 
reduce the drug concentration that decreased the effectiveness of therapy. Some practitioners assume the existence 
of renal portal system in reptile that lessens the drug concentration may resolve through anterior application only. 
The drug pharmacokinetics comparison study6 concluded that the choice of injection site had no effect on any 
gentamicin pharmacokinetic parameters, but found the lower value of Area Under Curve (AUC) of carbenicillin at 
posterior site injection in some point of intervals. Although it might reflect the reduced bioavailability, it was 
clinically not important because of the high level of drug in plasma. The other study7 compared the gentamicin 
injected in cranial and caudal limb musculature of eastern box turtle and found no clinically important differences on 
drug half-life and plasma concentration. This study aims at comparing the clinical application of amikacin by 
intravenous and intramuscular routes on anterior and posterior region in sanca batik snakes (Broghammerus 
reticulatus) to the concentration of drug at some intervals. 
2. Material and methods 
Sixteen adapted sanca batik snakes (Broghammerus reticulatus) were used, a python that is very common in rice 
fields or bush in Indonesia, weighing (3 to 8) kg. They had been maintained in individual cages for 10 d before the 
experiment started. The temperature was measured at (27 to 30) ºC. There was water but no food in the cages,  48 h 
prior to drug injection all snakes had a physical examination and none was diagnosed sick or injured. The animals 
were grouped into four (n=4) randomly. Group 1 and  group 2 were injected intravenously at caudal and sublingual 
veins, respectively; group 3 and  group 4 were injected intramuscularly at one third region of posterior and anterior 
musculatures, respectively. A day before the drug administration, the blood collected randomly from one snake of 
each group served as source for blank plasma for drug analysis validation. The injected dose of amikacin (Alostil®, 
manufactured by Prafa, PRAJA PHARIN, Citeureup, West Java) was 5 mg · kg–1 body weight4. The blood was 
collected by cardio-puncture into heparinized tube, centrifuged at 2 500 G to obtain plasma that was kept in the 
freezer until analysis. The sampling interval was done at 1 min (t1), and 60 min (t2), 24 h (t3) and 48 h (t4) after 
drug injection. Plasma was mixed 1 : 1 with trichloro-acetic acid (10 %), vortexed and centrifuged at 2 500 G for     
5 min. The supernatants were collected then analyzed for the drug concentration by High Performance Liquid 
Chromatography (HPLC). The system was set at room temperature (25 ºC), using the equipment from Shimadzu 
version 6.1, detector UV SPD-10A at 350 nm, column C18 Shimpack ODS 5 μm diameter and 150 mm length, LC-
10 ADvp, degasser DGU-14 and controller system SL-10Avp and managed with Class Vp software. The mobile 
phase was aqueous oxalic acid solution (0.126 %) : acetonitrile : methanol  = (6 : 3 : 1, v : v : v), the  flow  rate was 
1 mL · minute-1 and the volume of injection 20 μL. 
The concentration at each time point was measured as peak area an amikacin standard curve for calibration that 
had been made at a preliminary experiment of this study8 . The anterior and posterior data were classified and 
statistically analyzed with tests of normality and student t test. 
3. Result and discussion 
The amikacin concentration of groups as showed on Table 1 result in the highest and lowest values by i.v. 
posterior administration  (caudal vein) at minute 1 (t1) and intramuscular of anterior  at 48 h (t4) post injection, 
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respectively. These values have a statistically significant difference. As the result of Beck et al.7 the data of this 
study were similar that no clinically important difference of amikacin concentration administered posterior or 
anterior region accept at t1 i.v. and t4 i.m. Some articles and opinions suggest not to use the posterior region body of 
reptiles to administer the drug because of the existence of renal-portal system. The system allows the blood flow 
through the kidney before reaching the heart, and the drug could be eliminated by kidney. However, many previous 
studies resulted no clinically important difference of drug concentration irrespective of whatever it had been 
administered from front or rear of reptile body6,7. At the end of the experiments, none of the animals showed 
indication of being sick or injured, indicating no toxic effect of the amikacin dose given. In order to minimize 
nephrotoxicity, it has been suggested in other studies of aminoglycoside gentamicin in water snake and gopher 
snake, to divide the bolus or to wait for an undetectable drug level before giving the next dose1,9,10. However the 
study of gentamicin multiple dosing of (2.5 to 3) mg · kg–1 body weight as loading dose followed by 1.5 mg · kg–1 at 
72 h and 96 h in blood python had no evidence of renal toxicity 11.The renal-portal system study conducted by Holtz 
et al.6 explained that the effect of injection of gentamicin or carbenicillin in posterior region of red-eared slider to 
the level of drug will vary with its renal or hepatic extraction rate. Generally the study summarized that the effect of 
renal-portal system was unlikely to be significant on the pharmacokinetic parameters of drugs. 
 
Table 1. The mean ±SE concentration of  amikacin after single dose  (5 mg · kg–1 body weight) at posterior and anterior body region of   
sanca batik snake 
 
Sampling time      i.v. posterior      i.v. anterior    i.m. posterior             i.m. anterior 
    
 minute 1 
 minute 60 
 24 h 
 48 h 
 
81.90 ± 23.1aa 
41.43 ± 17.6 
34.43 ± 22.3 
30.80 ± 12.6 
20.14 ± 6.3aa 
21.20 ± 4.5 
20.22 ± 6.3 
19.05 ± 2.6 
 
   29.56 ± 18.65            13.35 ± 9.30 
   20.25 ±   7.96            17.70 ± 6.84           
     19.25 ±   7.91            10.37 ± 2.44 
   17.23 ±   5.29b             8.04 ± 0.45b 
 
Note : 
aasignificant (P < 0.01) 
bsignificant (P < 0.05) 
 
   
 
 
 
             
Fig. 1. (a) the comparison of amikacin concentration injected intravenously into caudal and sublingual veins ; (b) the comparison 
intramuscularly between posterior and anterior regions. The posterior application generated higher concentration outline. 
                                                                                   
As seen on Figure 1(a) and (b) the comparison of drug concentration describes that the higher level is reached by 
posterior administration. Both intravenous and intramuscular applications have the maximum concentration about 
the early time of injection. The intravenous at caudal vein curves profiles is similar to the intra-cardiac injection 
curve of Johnson et al. study of amikacin pharmacokinetics in ball python3. The intravenous injection into 
sublingual vein results in no specific profile that may be caused by unidentified factors. This route of application can 
be used safely in animal under anesthesia. The consistently higher level of intravenous appearances caused by the 
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higher level it received in the early time of injection. The intramuscular profiles of amikacin give the rapid 
absorption especially for the posterior region which is reached before 1 h post injection.  The curve of concentration 
by intramuscular injection (Figure 1b ) is similar to a study of gentamicin concentration between cranial and caudal 
musculature of the eastern box turtle by Beck7 either at posterior or anterior region.  
The maximum concentration of drug by intravenous injection at caudal vein (81.9 ± 23.1) μg · mL–1 is 
significantly different from sublingual vein (20.14 ± 6.3) μg · mL–1 either the 1/3 posterior musculature (17.23 ± 
5.29) μg · mL–1 and anterior (8.04 ± 0.45) μg · mL–1. At dosage of 5 mg · kg–1 body weight, at 48 h after injection 
the concentration of amikacin was still above the minimum inhibitory concentration (MIC) for some pathogenic 
microorganism isolated from snake. The MIC values for Pseudomonas aureginosa, Morganella, Aeromonas spp., 
Providencia spp. and Salmonella spp. ranged at (0.2 to 32) μg · mL–1  4,12,13. In gopher snake, the amikacin MIC was 
maintained until 6 d after i.m. administration with lower dose but with multiple injections3,4. For aminoglycoside, it 
is recommended to maintain (8 to 10) times concentration of MIC in plasma to be effective14. Although there were 
not enough data in this research to determine the t 1/2 , the elimination phase can be seen as the trend of drug decline 
in the (24 to 48) h. Based on the earlier study4 the amikacin half-life was reported 71.9 h at the 25 ºC temperature on 
gopher snake. Given the similarity of temperature and species it can be assumed that for (24 to 48) d the plasma 
concentration would still have the therapeutic value for some bacteria. To maintain the effectiveness to specific 
bacteria such as Salmonella sp. MIC (1 to 2) μg · mL–1 the serum concentration needs to achieve 8 μg . mL–1. The 
application of single dose of 5 mg · kg–1 body weight in this study seems to be effective toward Salmonella sp. and 
other bacteria with the same or lower of MIC value. However, to eradicate the bacteria with higher MIC such as 
Pseudomonas sp. (6 μg · mL–1 to 32 μg · mL–1) the dose has to be increased to achieve the (8 to 10) times of MIC.  
4. Conclusion 
The routes of administration of amikacin 5 mg · kg–1 body of weight from posterior or anterior region 
intravenously and intramuscularly on sanca batik snake (Broghammerus reticulatus) had no clinically important 
difference. The concentration comparison between i.v. or i.m. had statistically significant differences at minute 1 
and 48 h, but was not significant at other intervals. Based on the result of study, it is recommend that a dosage of 
amikacin in sanca batik snake is 5 mg · kg–1 i.m. from anterior or posterior region. After 48 h post administration 
the drug concentration in plasma was still above the MIC of some pathogenic bacteria. 
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